Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era?

Ababneh, Hazim S; Raje, Noopur S; Yee, Andrew J; Patel, Chirayu G

Ababneh, Hazim S; Raje, Noopur S; Yee, Andrew J; Patel, Chirayu G.

Afiliação

Ababneh HS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Raje NS; Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Yee AJ; Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Patel CG; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: cpatel@mgh.harvard.edu.

Pract Radiat Oncol ; 12(5): 367-369, 2022.

Article em En | MEDLINE | ID: mdl-36058616

Assuntos

Mieloma Múltiplo; Receptores de Antígenos Quiméricos; Humanos; Imunoterapia Adotiva; Mieloma Múltiplo/radioterapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Pract Radiat Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google